More intelligence articles

Assessing the risks in annuity pricing models

The challenge of adapting pricing models to accommodate new therapies

Creating value from value-based healthcare

Why pharma companies need to implement novel business models and more

Evolution or revolution: the latest review of NICE methods

By Leela Barham

Integrating patient reported outcomes into clinical trials

How capturing the patient voice is unlocking medicines’ commercial potential

A snapshot of Crescendo Biologics

PME talks to CEO Theodora Harold

The Golden Goose

Why it’s so hard for the US to curb runaway drug prices

Leading AstraZeneca’s return to growth in Europe

PME talks to Iskra Reic, the company’s head of Europe and Canada

Changing direction: adapting to a rapidly-evolving environment

Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace

Understanding the patient journey

What we can learn from customer service

Mastering data protection in the pharma industry

‘Trip wires’ that pharma should look out for

Darwinian leadership in the life sciences industry

Good leadership is about adapting to the exceptional features of our industry

Building European biotech firms to rival those of the US

PME speaks to Richard Mason on how drug discovery is evolving

European biotech: a new generation of leaders emerges

Three companies that are on the rise in biotech

Encouraging signs in biomarker R&D

The cancer immunotherapy firms ramping-up biomarker R&D

Detecting Alzheimer’s ahead of a cure

A focus on promising new research